查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1836320

神经免疫学药物市场，按产品类型、按适应症、按国家和地区 - 2025 年至 2032 年全球行业分析、市场规模、市场份额和预测

Neuroimmunology Drugs Market, By Product Type, By Indications, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 322 Pages | 商品交期: 2-3个工作天内

价格
简介目录

2024 年神经免疫学药物市场规模价值 258.151 亿美元，2025 年至 2032 年的复合年增长率为 9.90%。

神经免疫学药物主要用于治疗神经系统和免疫系统疾病。这包括视神经脊髓炎 (NMO)、多发性硬化症 (MS) 和其他自体免疫疾病等神经系统疾病。该领域的许多神经系统疾病被归类为自体免疫疾病，是指免疫系统错误识别并攻击神经系统组成部分（例如多发性硬化症 (MS) 中的髓鞘）而发生的疾病。

神经免疫学药物市场-市场动态

神经免疫疾病发生率不断上升

神经免疫疾病的盛行率不断上升，推动着神经免疫药物市场的成长。随着诊断数量的增加，对有效治疗的需求也随之增加，导致需要药物的患者群体不断扩大。这种需求的成长促使製药公司大力投资研发，从而推动了创新和新药的开发。不断增长的患者群体需要更广泛的治疗选择，促使科学家探索新的治疗策略和先进的药物前景。因此，这些疾病盛行率的上升与市场规模的扩大成正比，因为越来越多的患者寻求并需要神经免疫药物，从而推动了市场的成长。

神经免疫学药物市场-細項分析：

全球神经免疫学药物市场根据产品类型、适应症和地区进行细分。

根据产品类型，市场分为六大类：单株抗体、小分子、淋巴球、重组蛋白、细胞激素和其他产品类型。单株抗体通常用于治疗多发性硬化症 (MS) 和视神经脊髓炎 (NMO) 等神经免疫疾病，从而改善病情，因此单株抗体细分市场预计将快速成长。这些单株抗体旨在减轻发炎并抑制发炎反应，或许能够延缓病程并防止復发。发炎是许多神经免疫疾病的主要因素，单株抗体有助于缓解疼痛并防止神经组织进一步受损。某些单株抗体可以阻止自体免疫系统攻击髓鞘等神经系统元件，有助于预防神经损伤。

根据适应症，市场分为九类：多发性硬化症、阿兹海默症、重症肌无力症、格林巴利症候群、巴金森氏症、视神经脊髓炎谱系障碍、肌萎缩性侧索硬化症、慢性发炎性脱髓鞘多发性神经根神经病变和其他适应症。多发性硬化症 (MS) 是神经免疫学药物市场上最常见的神经系统疾病之一，预计该领域在预测期内将以最快的复合年增长率增长。在多发性硬化症 (MS) 这种自体免疫疾病中，免疫系统错误地攻击了包裹中枢神经系统 (CNS) 神经纤维的保护性髓鞘层。这种疾病会导致各种各样的神经系统症状。此外，由于正在进行的研究，新的治疗方法正在被开发，现有的药物正在被重新用于治疗多发性硬化症，这些尖端治疗的目标是获得更好的结果和更多的治疗选择。

神经免疫学药物市场-地理洞察

预计亚太地区将在预测期内占据最大的市场份额，因为多发性硬化症、视神经脊髓炎和其他自体免疫神经系统疾病等神经免疫疾病在亚太地区日益增加。由于治疗方案的改进、早期发现以及对神经免疫疾病认知的提高，每个国家和地区的盛行率都各有不同。一些地区政府正在努力改善神经免疫疾病的管理，包括资助研究、扩大医疗基础设施以及鼓励早期发现和介入。

由于北美地区神经免疫学相关药物临床试验的普及，预计在预测期内的复合年增长率最高。北美拥有强大的医疗保健体系、研究机构和多样化的患者群体，是开展临床研究的理想之地。美国食品药物管理局 (FDA) 和加拿大卫生部是两大监管机构，负责确保神经免疫学药物的安全性和有效性，并建立了明确的药品审批监管框架。在北美，许多患者拥有医疗保险，这有助于降低自付治疗费用，并改善神经免疫学药物的可近性。

神经免疫学药物市场-竞争格局：

神经免疫药物市场竞争激烈，多家主要参与者争夺市场份额。 Biogen、Hoffmann-La Roche Ltd、T3D Therapeutics 和 Novartis AG 等大型製药公司处于领先地位，大力投资研发，致力于将创新疗法推向市场。这些公司通常拥有针对各种神经免疫疾病的多样化药物组合。规模较小的生物技术公司和新兴企业也在为市场做出贡献，其中许多专注于特定的治疗领域或新型药物开发策略。推动竞争的因素包括药物疗效、安全性、定价策略以及获得监管部门批准和市场准入的能力。在这个动盪的市场中，合作、伙伴关係和收购是常见的策略，因为各公司都在寻求多元化产品组合併巩固其市场地位。

目录

第 1 章：神经免疫学药物市场概述

  • 研究范围
  • 市场估计年限

第 2 章：执行摘要

  • 市场片段
    • 神经免疫学药物市场按产品类型细分
    • 神经免疫学药物市场片段（按适应症）
    • 神经免疫学药物市场（按国家/地区）
    • 神经免疫学药物市场按地区划分
  • 竞争洞察

第三章：神经免疫学药物主要市场趋势

  • 神经免疫学药物市场驱动因素
    • 市场驱动因素的影响分析
  • 神经免疫学药物市场限制
    • 市场限制的影响分析
  • 神经免疫药物市场机会
  • 神经免疫学药物市场未来趋势

第四章：神经免疫学药物产业研究

  • PEST分析
  • 波特五力分析
  • 成长前景图
  • 规范架构分析

第五章：神经免疫学药物市场：地缘政治紧张局势升级的影响

  • COVID-19 疫情的影响
  • 俄乌战争的影响
  • 中东衝突的影响

第六章：神经免疫学药物市场格局

  • 2024年神经免疫学药物市场份额分析
  • 按主要製造商分類的细分数据
    • 成熟玩家分析
    • 新兴企业分析

第七章：神经免疫药物市场－依产品类型

  • 概述
    • 按产品类型分類的细分市场占有率分析
    • 单株抗体
    • 小分子
    • 淋巴球
    • 重组蛋白
    • 细胞因子
    • 其他产品类型

第 8 章：神经免疫药物市场 - 按适应症

  • 概述
    • 按适应症分類的细分市场占有率分析
    • 多发性硬化症
    • 阿兹海默症
    • 重症肌无力
    • 格林-巴利综合症
    • 帕金森氏症
    • 视神经脊髓炎谱系障碍
    • 肌萎缩侧索硬化症
    • 慢性发炎性脱髓鞘多发性神经根神经病变
    • 其他适应症

第九章：神经免疫学药物市场－按地区划分

  • 介绍
    • 按地区分類的细分市场占有率分析
  • 北美洲
    • 概述
    • 北美神经免疫药物主要製造商
    • 北美市场规模及预测（按国家/地区）
    • 北美市场规模和预测（按产品类型）
    • 北美市场规模及预测（依指标）
    • 我们
    • 加拿大
  • 欧洲
    • 概述
    • 欧洲神经免疫药物主要製造商
    • 欧洲市场规模及预测（按国家/地区）
    • 欧洲市场规模和预测（按产品类型）
    • 欧洲市场规模及预测（依指标）
    • 德国
    • 英国
    • 法国
    • 义大利
    • 西班牙
    • 荷兰
    • 瑞典
    • 俄罗斯
    • 波兰
    • 欧洲其他地区
  • 亚太地区（APAC）
    • 概述
    • 亚太地区神经免疫药物主要製造商
    • 亚太地区市场规模及预测（依国家）
    • 亚太地区市场规模及预测（依产品类型）
    • 亚太地区市场规模及预测（依指标）
    • 中国
    • 印度
    • 日本
    • 韩国
    • 澳洲
    • 印尼
    • 泰国
    • 菲律宾
    • 亚太地区其他地区
  • 拉丁美洲（LATAM）
    • 概述
    • 拉丁美洲神经免疫药物主要製造商
    • 拉丁美洲市场规模及预测（按国家/地区）
    • 拉丁美洲市场规模及预测（依产品类型）
    • 拉丁美洲市场规模及预测（依指标）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥伦比亚
    • 拉丁美洲其他地区
  • 中东和非洲（MEA）
    • 概述
    • 中东和非洲神经免疫药物主要製造商
    • MEA 市场规模及预测（依国家/地区）
    • MEA 市场规模及预测（依产品类型）
    • MEA 市场规模及预测（依适应症）
    • 沙乌地阿拉伯
    • 阿联酋
    • 以色列
    • 土耳其
    • 阿尔及利亚
    • 埃及
    • MEA 其余地区

第 10 章：关键供应商分析-神经免疫学药物产业

  • 竞争基准化分析
    • Competitive Dashboard
    • Competitive Positioning
  • 公司简介
    • Biogen
    • Hoffmann-La Roche Ltd
    • T3D Therapeutics
    • Novartis AG
    • Johnson & Johnson
    • Celgene Corp
    • Merck KGaA
    • Eisai Co Ltd
    • Sanofi
    • Actelion Pharmaceuticals Ltd
    • ImmunoBrain Checkpoint
    • Lundbeck, Eli Lilly
    • AstraZeneca
    • UCB SA
    • AB Science SA
    • AstronauTx, Genetech Inc
    • Inflammasome Therapeutics
    • TauRX Therapeutics Ltd
    • Others

第 11 章：360 度分析师视角

第 12 章：附录

  • 研究方法
  • 参考
  • 缩写
  • 免责声明
  • 联络我们
简介目录
Product Code: ANV5605

Neuroimmunology Drugs Market size was valued at US$ 25,815.10 Million in 2024, expanding at a CAGR of 9.90% from 2025 to 2032.

Neuroimmunology drugs are primarily used to treat neurological and immune system disorders. This includes neurological conditions such as neuromyelitis optica (NMO), multiple sclerosis (MS), and other autoimmune diseases. Many neurological disorders in this area are classified as autoimmune illnesses, which occur when the immune system misidentifies and attacks nervous system components, such as the myelin sheath in multiple sclerosis (MS).

Neuroimmunology Drugs Market- Market Dynamics

Increasing incidence of neuroimmunological disorders

The increasing prevalence of neuroimmunological disorders is driving market growth in the neuroimmunology drugs sector. As diagnoses rises the demand for effective treatments, resulting in a larger patient pool who require medication. This increased demand encourages pharmaceutical companies to invest heavily in R&D, which drives innovation and the development of new drugs. The growing patient population necessitates a broader range of therapeutic options, prompting scientists to investigate novel strategies and advanced drug prospects. As a result, the increasing prevalence of these disorders is directly proportional to increased market size, as more patients seek and require neuroimmunology drugs, driving market growth.

Neuroimmunology Drugs Market- Key Insights

Our research analyst estimates that the global market will grow at a CAGR of approximately 9.90% between 2025 and 2032.

Monoclonal antibodies are expected to have the highest market share in 2025.

Multiple sclerosis is the leading indication segment in 2025.

Asia Pacific is projected to generate the most revenue in 2025.

Neuroimmunology Drugs Market- Segmentation Analysis:

The Global Neuroimmunology Drugs Market is segmented on the basis of Product Type, Indications, and Region.

The market is divided into six categories based on product type: Monoclonal Antibodies, Small Molecules, Lymphocytes, Recombinant Protein, Cytokines, and Other Product Types. Monoclonal antibodies are commonly used as disease-modifying treatments for neuroimmunological conditions such as multiple sclerosis (MS) and neuromyelitis optica (NMO), so the monoclonal antibody segment is expected to grow rapidly. These mAbs, which aim to reduce inflammation and suppress the inflammatory response, may be able to slow the course of the illness and prevent relapses. Inflammation is a major factor in many neuroimmunological illnesses, and monoclonal antibodies can help to relieve pain and prevent further nerve tissue damage. Certain mAbs prevent the autoimmune system from attacking nervous system elements such as the myelin sheath, thereby aiding in the prevention of neurological damage.

The market is divided into nine categories based on Indications: Multiple Sclerosis, Alzheimer's Disease, Myasthenia Gravis, Guillain-Barre Syndrome, Parkinson's Disease, Neuromyelitis Optica Spectrum Disorder, Amyotrophic Lateral Sclerosis, Chronic Inflammatory Demyelinating Polyradiculoneuropathy, and Other Indications. Multiple sclerosis (MS) is one of the most common neurological disorders in the market for neuroimmunology medications, and the segment is expected to grow at the fastest CAGR during the forecast period. The immune system incorrectly attacks the protective myelin layer that envelops nerve fibers in the central nervous system (CNS) in multiple sclerosis (MS), an autoimmune disease. This illness causes a wide range of neurological symptoms. Furthermore, as a result of ongoing research, novel treatments are being developed and existing medications are being repurposed for the treatment of multiple sclerosis, with the goals of these cutting-edge treatments being better results and more treatment options.

Neuroimmunology Drugs Market- Geographical Insights

Asia Pacific is expected to have the largest market share during the forecast period, as neuroimmunological diseases such as multiple sclerosis, neuromyelitis optical, and other autoimmune nervous system illnesses have become more common in the Asia Pacific region. Each country and region has a unique precise prevalence as a result of improved treatment options, early detection, and increased awareness of neuroimmunological illnesses. Several regional governments are working to improve neuroimmunological disease management. This includes funding for research, expanding the healthcare infrastructure, and encouraging early detection and intervention.

North America is expected to have the highest CAGR over the forecast period, owing to the prevalence of clinical trials for neuroimmunology-related medications in the region. It's a desirable location for clinical research due to its strong healthcare system, research institutes, and diverse patient population. The United States Food and Drug Administration (FDA) and Health Canada are two regulatory bodies that ensure the safety and efficacy of neuroimmunology medications, establishing a well-defined regulatory framework for drug approval. In North America, many patients have health insurance, which can help to reduce out-of-pocket treatment costs and improve access to neuroimmunology medications.

Neuroimmunology Drugs Market- Competitive Landscape:

The neuroimmunology drugs market is competitive, with several key players vying for market share. Major pharmaceutical companies such as Biogen, Hoffmann-La Roche Ltd, T3D Therapeutics, and Novartis AG are leading the way, investing heavily in R&D to bring innovative treatments to market. These companies frequently have a diverse portfolio of drugs that target various neuroimmunological disorders. Smaller biotechnology companies and emerging players are also contributing to the market, with many focusing on specific therapeutic areas or novel drug development strategies. Factors driving competition include drug efficacy, safety profiles, pricing strategies, and the ability to obtain regulatory approvals and market access. Collaborations, partnerships, and acquisitions are common strategies in this volatile market, as companies seek to diversify their product portfolios and strengthen their market positions.

Recent Developments:

In June 2023, Roche announced that it had signed a definitive agreement to acquire Telavant Holdings, Inc. (Telavant), a Roivant company owned by Roivant Sciences Ltd. and Pfizer Inc. Telavant's RVT-3101 will be developed, manufactured, and commercialised in the United States and Japan under the terms of the agreement.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL NEUROIMMUNOLOGY DRUGS MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • Biogen
  • Hoffmann-La Roche Ltd
  • T3D Therapeutics
  • Novartis AG
  • Johnson & Johnson
  • Celgene Corp
  • Merck KGaA
  • Eisai Co Ltd
  • Sanofi
  • Actelion Pharmaceuticals Ltd
  • ImmunoBrain Checkpoint
  • Lundbeck, Eli Lilly
  • AstraZeneca
  • UCB SA
  • AB Science S.A
  • AstronauTx, Genetech Inc
  • Inflammasome Therapeutics
  • TauRX Therapeutics Ltd
  • Others

GLOBAL NEUROIMMUNOLOGY DRUGS MARKET, BY PRODUCT TYPE- MARKET ANALYSIS, 2019 - 2032

  • Monoclonal Antibodies
  • Small Molecules
  • Lymphocytes
  • Recombinant Protein
  • Cytokines
  • Other Product Types

GLOBAL NEUROIMMUNOLOGY DRUGS MARKET, BY INDICATIONS- MARKET ANALYSIS, 2019 - 2032

  • Multiple Sclerosis
  • Alzheimer's Disease
  • Myasthenia Gravis
  • Guillain-Barre Syndrome
  • Parkinson's Disease
  • Neuromyelitis Optica Spectrum Disorder
  • Amyotrophic Lateral Sclerosis
  • Chronic Inflammatory Demyelinating Polyradiculoneuropathy
  • Other Indications

GLOBAL NEUROIMMUNOLOGY DRUGS MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Neuroimmunology Drugs Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Neuroimmunology Drugs Market Snippet by Product Type
    • 2.1.2. Neuroimmunology Drugs Market Snippet by Indications
    • 2.1.3. Neuroimmunology Drugs Market Snippet by Country
    • 2.1.4. Neuroimmunology Drugs Market Snippet by Region
  • 2.2. Competitive Insights

3. Neuroimmunology Drugs Key Market Trends

  • 3.1. Neuroimmunology Drugs Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Neuroimmunology Drugs Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Neuroimmunology Drugs Market Opportunities
  • 3.4. Neuroimmunology Drugs Market Future Trends

4. Neuroimmunology Drugs Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Neuroimmunology Drugs Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Neuroimmunology Drugs Market Landscape

  • 6.1. Neuroimmunology Drugs Market Share Analysis, 2024
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Neuroimmunology Drugs Market - By Product Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Product Type, 2024 & 2032 (%)
    • 7.1.2. Monoclonal Antibodies
    • 7.1.3. Small Molecules
    • 7.1.4. Lymphocytes
    • 7.1.5. Recombinant Protein
    • 7.1.6. Cytokines
    • 7.1.7. Other Product Types

8. Neuroimmunology Drugs Market - By Indications

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Indications, 2024 & 2032 (%)
    • 8.1.2. Multiple Sclerosis
    • 8.1.3. Alzheimer's Disease
    • 8.1.4. Myasthenia Gravis
    • 8.1.5. Guillain-Barre Syndrome
    • 8.1.6. Parkinson's Disease
    • 8.1.7. Neuromyelitis Optica Spectrum Disorder
    • 8.1.8. Amyotrophic Lateral Sclerosis
    • 8.1.9. Chronic Inflammatory Demyelinating Polyradiculoneuropathy
    • 8.1.10. Other Indications

9. Neuroimmunology Drugs Market- By Geography

  • 9.1. Introduction
    • 9.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
  • 9.2. North America
    • 9.2.1. Overview
    • 9.2.2. Neuroimmunology Drugs Key Manufacturers in North America
    • 9.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 9.2.4. North America Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 9.2.5. North America Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
    • 9.2.6. U.S.
      • 9.2.6.1. Overview
      • 9.2.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.2.6.3. U.S. Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 9.2.6.4. U.S. Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
    • 9.2.7. Canada
      • 9.2.7.1. Overview
      • 9.2.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.2.7.3. Canada Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 9.2.7.4. Canada Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
  • 9.3. Europe
    • 9.3.1. Overview
    • 9.3.2. Neuroimmunology Drugs Key Manufacturers in Europe
    • 9.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 9.3.4. Europe Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 9.3.5. Europe Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
    • 9.3.6. Germany
      • 9.3.6.1. Overview
      • 9.3.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.6.3. Germany Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 9.3.6.4. Germany Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
    • 9.3.7. UK
      • 9.3.7.1. Overview
      • 9.3.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.7.3. UK Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 9.3.7.4. UK Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
    • 9.3.8. France
      • 9.3.8.1. Overview
      • 9.3.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.8.3. France Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 9.3.8.4. France Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
    • 9.3.9. Italy
      • 9.3.9.1. Overview
      • 9.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.9.3. Italy Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 9.3.9.4. Italy Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
    • 9.3.10. Spain
      • 9.3.10.1. Overview
      • 9.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.10.3. Spain Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 9.3.10.4. Spain Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
    • 9.3.11. The Netherlands
      • 9.3.11.1. Overview
      • 9.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.11.3. The Netherlands Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 9.3.11.4. The Netherlands Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
    • 9.3.12. Sweden
      • 9.3.12.1. Overview
      • 9.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.12.3. Sweden Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 9.3.12.4. Sweden Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
    • 9.3.13. Russia
      • 9.3.13.1. Overview
      • 9.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.13.3. Russia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 9.3.13.4. Russia Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
    • 9.3.14. Poland
      • 9.3.14.1. Overview
      • 9.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.14.3. Poland Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 9.3.14.4. Poland Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
    • 9.3.15. Rest of Europe
      • 9.3.15.1. Overview
      • 9.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.3.15.3. Rest of the Europe Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 9.3.15.4. Rest of the Europe Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
  • 9.4. Asia Pacific (APAC)
    • 9.4.1. Overview
    • 9.4.2. Neuroimmunology Drugs Key Manufacturers in Asia Pacific
    • 9.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 9.4.4. APAC Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 9.4.5. APAC Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
    • 9.4.6. China
      • 9.4.6.1. Overview
      • 9.4.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.6.3. China Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 9.4.6.4. China Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
    • 9.4.7. India
      • 9.4.7.1. Overview
      • 9.4.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.7.3. India Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 9.4.7.4. India Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
    • 9.4.8. Japan
      • 9.4.8.1. Overview
      • 9.4.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.8.3. Japan Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 9.4.8.4. Japan Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
    • 9.4.9. South Korea
      • 9.4.9.1. Overview
      • 9.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.9.3. South Korea Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 9.4.9.4. South Korea Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
    • 9.4.10. Australia
      • 9.4.10.1. Overview
      • 9.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.10.3. Australia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 9.4.10.4. Australia Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
    • 9.4.11. Indonesia
      • 9.4.11.1. Overview
      • 9.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.11.3. Indonesia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 9.4.11.4. Indonesia Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
    • 9.4.12. Thailand
      • 9.4.12.1. Overview
      • 9.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.12.3. Thailand Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 9.4.12.4. Thailand Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
    • 9.4.13. Philippines
      • 9.4.13.1. Overview
      • 9.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.13.3. Philippines Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 9.4.13.4. Philippines Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
    • 9.4.14. Rest of APAC
      • 9.4.14.1. Overview
      • 9.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.4.14.3. Rest of APAC Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 9.4.14.4. Rest of APAC Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
  • 9.5. Latin America (LATAM)
    • 9.5.1. Overview
    • 9.5.2. Neuroimmunology Drugs Key Manufacturers in Latin America
    • 9.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 9.5.4. LATAM Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 9.5.5. LATAM Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
    • 9.5.6. Brazil
      • 9.5.6.1. Overview
      • 9.5.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.5.6.3. Brazil Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 9.5.6.4. Brazil Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
    • 9.5.7. Mexico
      • 9.5.7.1. Overview
      • 9.5.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.5.7.3. Mexico Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 9.5.7.4. Mexico Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
    • 9.5.8. Argentina
      • 9.5.8.1. Overview
      • 9.5.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.5.8.3. Argentina Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 9.5.8.4. Argentina Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
    • 9.5.9. Colombia
      • 9.5.9.1. Overview
      • 9.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.5.9.3. Colombia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 9.5.9.4. Colombia Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
    • 9.5.10. Rest of LATAM
      • 9.5.10.1. Overview
      • 9.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.5.10.3. Rest of LATAM Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 9.5.10.4. Rest of LATAM Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
  • 9.6. Middle East and Africa (MEA)
    • 9.6.1. Overview
    • 9.6.2. Neuroimmunology Drugs Key Manufacturers in Middle East and Africa
    • 9.6.3. MEA Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 9.6.4. MEA Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
    • 9.6.5. MEA Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
    • 9.6.6. Saudi Arabia
      • 9.6.6.1. Overview
      • 9.6.6.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.6.3. Saudi Arabia Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 9.6.6.4. Saudi Arabia Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
    • 9.6.7. UAE
      • 9.6.7.1. Overview
      • 9.6.7.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.7.3. UAE Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 9.6.7.4. UAE Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
    • 9.6.8. Israel
      • 9.6.8.1. Overview
      • 9.6.8.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.8.3. Israel Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 9.6.8.4. Israel Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
    • 9.6.9. Turkey
      • 9.6.9.1. Overview
      • 9.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.9.3. Turkey Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 9.6.9.4. Turkey Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
    • 9.6.10. Algeria
      • 9.6.10.1. Overview
      • 9.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.10.3. Algeria Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 9.6.10.4. Algeria Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
    • 9.6.11. Egypt
      • 9.6.11.1. Overview
      • 9.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.11.3. Egypt Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 9.6.11.4. Egypt Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)
    • 9.6.12. Rest of MEA
      • 9.6.12.1. Overview
      • 9.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 9.6.12.3. Rest of MEA Market Size and Forecast, By Product Type, 2019 - 2032 (US$ Million)
      • 9.6.12.4. Rest of MEA Market Size and Forecast, By Indications, 2019 - 2032 (US$ Million)

10. Key Vendor Analysis- Neuroimmunology Drugs Industry

  • 10.1. Competitive Benchmarking
    • 10.1.1. Competitive Dashboard
    • 10.1.2. Competitive Positioning
  • 10.2. Company Profiles
    • 10.2.1. Biogen
    • 10.2.2. Hoffmann-La Roche Ltd
    • 10.2.3. T3D Therapeutics
    • 10.2.4. Novartis AG
    • 10.2.5. Johnson & Johnson
    • 10.2.6. Celgene Corp
    • 10.2.7. Merck KGaA
    • 10.2.8. Eisai Co Ltd
    • 10.2.9. Sanofi
    • 10.2.10. Actelion Pharmaceuticals Ltd
    • 10.2.11. ImmunoBrain Checkpoint
    • 10.2.12. Lundbeck, Eli Lilly
    • 10.2.13. AstraZeneca
    • 10.2.14. UCB SA
    • 10.2.15. AB Science S.A
    • 10.2.16. AstronauTx, Genetech Inc
    • 10.2.17. Inflammasome Therapeutics
    • 10.2.18. TauRX Therapeutics Ltd
    • 10.2.19. Others

11. 360 Degree AnalystView

12. Appendix

  • 12.1. Research Methodology
  • 12.2. References
  • 12.3. Abbreviations
  • 12.4. Disclaimer
  • 12.5. Contact Us